Cargando…
Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects
Blocking the CD40–CD154 interaction is reported to be effective for transplantation management and autoimmune disease models in rodents and nonhuman primates. However, clinical trials with anti-CD154 mAbs were halted because of high incidence of thromboembolic complications. Thus, we generated and c...
Autores principales: | Okimura, K, Maeta, K, Kobayashi, N, Goto, M, Kano, N, Ishihara, T, Ishikawa, T, Tsumura, H, Ueno, A, Miyao, Y, Sakuma, S, Kinugasa, F, Takahashi, N, Miura, T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225473/ https://www.ncbi.nlm.nih.gov/pubmed/24731050 http://dx.doi.org/10.1111/ajt.12678 |
Ejemplares similares
-
Pharmacokinetics and Pharmacodynamics of ASKP1240, a Fully Human Anti-CD40 Antibody, in Normal and Renal Transplanted Cynomolgus Monkeys
por: Ma, Anlun, et al.
Publicado: (2014) -
Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys
por: Song, Lijun, et al.
Publicado: (2014) -
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
por: Anil Kumar, Mysore S., et al.
Publicado: (2018) -
P1240: MICROBIOME DIVERSITY IN PATIENTS WITH LYMPHOMA
por: Dlouha, Lucie, et al.
Publicado: (2023) -
PReS13-SPK-1240: New aspects on APS pathogenesis
por: Meroni, PL
Publicado: (2013)